Latest Research Report on Immunofluorescence Assay Market Growth, Industry Revenue Analysis

Immunofluorescence assay is a powerful technique used to analyze the distribution of glycans, proteins, and small biological and non-biological molecules (cells and tissues) using antibodies conjugated with a fluorescent dye, known as fluorophore, which can be visualized using a fluorescence microscope or imaging systems.

The Immunofluorescence Assay market is expected to reach USD 2.01 Billion by 2023 from USD 1.43 Billion in 2017, at a CAGR of 5.8%

The increasing prevalence of chronic diseases, increasing R&D spending, and increasing healthcare spending are the major factors driving the growth of the market. The base year considered for the study is 2017 and the forecast period includes 2018 to 2023.

+ Market Dynamics

+ Drivers

+ Increasing Prevalence of Chronic Diseases

+ Increasing R&D Spending

+ Increasing Healthcare Spending

Download PDF Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=255585571

The increasing prevalence of chronic diseases, increasing R&D spending, and increasing healthcare spending are the major factors driving the growth of the market.

The report analyzes the global market by product, type, disease, end user, and region. On the basis of product, the reagents segment accounted for the largest share of the global market in 2017. The growing applications of biosciences and biotechnology within the pharmaceutical and healthcare fields, the rising prevalence of a number of diseases, growing R&D activities, and government initiatives to strengthen national research capabilities are the factors attributing for the largest share of the reagents segment.

The global market is segmented into indirect and direct immunofluorescence. In 2017, the indirect immunofluorescence accounted for the largest share of the market. The advantages of this technique, such as its sensitivity, flexibility, better amplification of the signal, and lower cost over direct immunofluorescence is the key factor increasing the adoption of this technique.

The infectious diseases segment accounted for the largest share of the global immunofluorescence assay market in 2017. The large share of this segment is attributed to the increasing prevalence of infectious diseases across the globe and the widespread adoption of immunofluorescence techniques for the study and diagnosis of infectious diseases.

High cost of immunofluorescence instruments and implementation of excise duty by the US government are the factors restraining the growth of the global immunofluorescence assay market.

The prominent players in the global market are Thermo Fisher (US), Inova Diagnostics (US), Bio-Rad (US), Abcam (UK), PerkinELmer (US), Merck Millipore (US), Cell Signaling Technology (US), MEDIPAN GMBH (Germany), Sino Biological (China), Danaher (US), and Vector Laboratories (US).

Geographically, the global market is segmented into North America, Europe, Asia Pacific, and Rest of the World. In 2017, North America accounted for the largest share of the market, followed by Europe and Asia Pacific. The rising incidence of chronic diseases, increasing R&D spending, increasing research activities, favorable government funding opportunities, and the presence of key players in this region are the major factors driving the growth of the immunofluorescence assay market in North America.

View complete press release:-https://www.marketsandmarkets.com/PressReleases/immunofluorescence-assay.asp

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche